The Use of Single Dose of Rasburicase for the Prophylaxis and Treatment of Tumor Lysis Syndrome in Pediatric Patients: A Narrative Review

Anselm Chi-wai Lee · 2025

Read The Use of Single Dose of Rasburicase for the Prophylaxis and Treatment of Tumor Lysis Syndrome in Pediatric Patients: A Narrative Review by Anselm Chi-wai Lee (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12732761.txt.

Description

Anselm Chi-wai Lee reviews single dose use of a drug for a cancer care emergency in children, in a 2025 paper. The emergency arises when tumor cells break down fast and flood the blood with waste. The drug, named once here as rasburicase, is licensed as a five day course.

Lee gathered all reports in which children got just one dose. Twelve papers with more than two hundred children met the test for success, meaning blood waste levels returned to normal without grave harm. Higher single doses worked far more often than low ones. Lee advises a set dose of at least three milligrams, or a weight based dose at the level he names.

Catalog record

CREATORAnselm Chi-wai Lee
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE31 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12732761

Browse the full library · About the Tower of Babel